Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11892042 | 1.00 | QPCT (0.69) | QPCTQPCTL | |
| SCHEMBL11892035 | 0.88 | QPCT (0.68) | QPCTQPCTL | |
| SCHEMBL3637926 | 0.88 | QPCT (0.68) | QPCTQPCTL | |
| SCHEMBL11892045 | 0.84 | QPCT (0.68) | QPCTQPCTL | |
| SCHEMBL3641720 | 0.84 | QPCT (0.68) | QPCTQPCTL | |
| SCHEMBL3628223 | 0.82 | QPCT (1.00) | QPCTQPCTL | |
| SCHEMBL8181969 | 0.82 | QPCT (0.77) | QPCTQPCTL | |
| SCHEMBL3639336 | 0.81 | QPCT (0.69) | QPCTQPCTL | |
| SCHEMBL11892023 | 0.81 | QPCT (0.69) | QPCTQPCTL | |
| SCHEMBL10005945 | 0.81 | QPCT (0.69) | QPCTQPCTL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3658141-B1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPALPHA - CD47 INTERACTION | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2022-11-16 | — | — | EP | claimed |
| US-8227498-B2 | imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 2-cyano(4-ethylphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)guanidine | PROBIODRUG AG (DE) | 2012-07-24 | — | — | US | claimed |
| EP-2160380-A1 | CYANO-GUANIDINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | Probiodrug AG (DE) | 2010-03-10 | — | — | EP | claimed |
| US-20080267912-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-30 | — | — | US | claimed |
| WO-2008128983-A1 | CYANO-GUANIDINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | claimed |
| EP-3658141-B1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPALPHA - CD47 INTERACTION | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2022-11-16 | — | — | EP | disclosed |
| US-20220087981-A1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA-CD47 INTERACTION | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis (NL) | 2022-03-24 | — | — | US | disclosed |
| EP-3747437-A1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA - CD47 INTERACTION | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2020-12-09 | — | — | EP | disclosed |
| EP-3747438-A1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA - CD47 INTERACTION | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2020-12-09 | — | — | EP | disclosed |
| EP-3658141-A1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA - CD47 INTERACTION | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2020-06-03 | — | — | EP | disclosed |
| WO-2019022600-A1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA - CD47 INTERACTION | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis (NL) | 2019-01-31 | — | — | WO | disclosed |
| EP-2606129-B1 | CRYSTAL STRUCTURE OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2015-03-25 | — | — | EP | disclosed |
| EP-2606129-A1 | CRYSTAL STRUCTURE OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2013-06-26 | — | — | EP | disclosed |
| US-8409837-B2 | Crystal structure of glutaminyl cyclase | PROBIODRUG AG (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8227498-B2 | imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 2-cyano(4-ethylphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)guanidine | PROBIODRUG AG (DE) | 2012-07-24 | — | — | US | disclosed |
| WO-2012022804-A1 | CRYSTAL STRUCTURE OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-02-23 | — | — | WO | disclosed |
| US-20120045815-A1 | CRYSTAL STRUCTURE OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-02-23 | — | — | US | disclosed |
| EP-2160380-A1 | CYANO-GUANIDINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | Probiodrug AG (DE) | 2010-03-10 | — | — | EP | disclosed |
| US-20080267912-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-30 | — | — | US | disclosed |
| WO-2008128983-A1 | CYANO-GUANIDINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080267912-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, QPCT | QPCT 3/4885QPCTL 14/4885 |
| US-20220087981-A1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA-CD47 INTERACTION | QPCT, QPCTL, CD47 | QPCT 1/4885QPCTL 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.